NEA Management Company as of Sept. 30, 2019
Portfolio Holdings for NEA Management Company
NEA Management Company holds 46 positions in its portfolio as reported in the September 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Allakos (ALLK) | 14.8 | $178M | 2.3M | 78.63 | |
| Ra Pharmaceuticals | 12.0 | $145M | 6.1M | 23.65 | |
| Rhythm Pharmaceuticals (RYTM) | 8.8 | $106M | 4.9M | 21.59 | |
| Crispr Therapeutics (CRSP) | 7.1 | $86M | 2.1M | 40.99 | |
| Network Associates Inc cl a (NET) | 6.2 | $75M | 4.1M | 18.57 | |
| Ardelyx (ARDX) | 6.0 | $72M | 15M | 4.70 | |
| Epizyme | 3.7 | $45M | 4.4M | 10.31 | |
| Mirum Pharmaceuticals (MIRM) | 3.5 | $42M | 4.2M | 10.06 | |
| Glycomimetics (GLYC) | 3.2 | $39M | 9.1M | 4.31 | |
| Obseva Sa | 3.2 | $38M | 4.6M | 8.33 | |
| Senseonics Hldgs (SENS) | 2.5 | $31M | 31M | 0.99 | |
| Aurinia Pharmaceuticals (AUPH) | 2.3 | $28M | 5.2M | 5.34 | |
| Phasebio Pharmaceuticals (PHASQ) | 2.3 | $28M | 6.6M | 4.17 | |
| Marker Therapeutics Ord | 2.1 | $26M | 5.0M | 5.11 | |
| Adaptimmune Therapeutics (ADAP) | 2.0 | $24M | 16M | 1.51 | |
| Dermira | 1.9 | $22M | 3.5M | 6.39 | |
| AVEO Pharmaceuticals | 1.8 | $21M | 25M | 0.84 | |
| Genocea Biosciences | 1.7 | $21M | 7.2M | 2.90 | |
| Trevi Therapeutics (TRVI) | 1.7 | $20M | 4.4M | 4.50 | |
| Mersana Therapeutics (MRSN) | 1.6 | $19M | 12M | 1.58 | |
| Affimed Therapeutics B V | 1.2 | $15M | 5.1M | 2.94 | |
| Millendo Therapeutics | 1.0 | $13M | 1.8M | 7.11 | |
| Strongbridge Bioph shs usd | 0.8 | $9.9M | 4.1M | 2.39 | |
| Mei Pharma | 0.8 | $9.6M | 5.7M | 1.68 | |
| Synlogic | 0.8 | $9.7M | 4.2M | 2.29 | |
| Champions Oncology (CSBR) | 0.7 | $8.8M | 1.6M | 5.65 | |
| Dasan Zhone Solutions | 0.7 | $8.8M | 956k | 9.16 | |
| Liquidia Technologies (LQDA) | 0.7 | $8.9M | 2.5M | 3.56 | |
| Lexicon Pharmaceuticals (LXRX) | 0.6 | $7.2M | 2.4M | 3.01 | |
| Rigel Pharmaceuticals (RIGL) | 0.5 | $6.1M | 3.2M | 1.87 | |
| Verona Pharma Plc ads (VRNA) | 0.5 | $5.6M | 1.2M | 4.57 | |
| Xenon Pharmaceuticals (XENE) | 0.5 | $5.4M | 603k | 9.01 | |
| Proteostasis Therapeutics In | 0.4 | $4.7M | 5.6M | 0.84 | |
| Surface Oncology | 0.4 | $4.7M | 3.3M | 1.42 | |
| Bloom Energy Corp (BE) | 0.4 | $4.3M | 1.3M | 3.25 | |
| X4 Pharmaceuticals (XFOR) | 0.3 | $4.2M | 333k | 12.71 | |
| Trevena | 0.3 | $3.7M | 3.8M | 0.97 | |
| Cti Biopharma | 0.3 | $3.2M | 3.8M | 0.84 | |
| Erytech Pharma Sa | 0.2 | $2.6M | 625k | 4.23 | |
| Tracon Pharmaceuticals | 0.1 | $1.6M | 3.5M | 0.45 | |
| Regulus Therapeutics | 0.1 | $1.5M | 2.1M | 0.72 | |
| Endologix | 0.1 | $989k | 249k | 3.97 | |
| Sunesis Pharmaceuticals Inc Ne | 0.1 | $935k | 1.3M | 0.72 | |
| Akari Therapeutics | 0.1 | $773k | 452k | 1.71 | |
| Trillium Therapeutics, Inc. Cmn | 0.1 | $651k | 2.1M | 0.31 | |
| Achaogen | 0.0 | $52k | 5.2M | 0.01 |
